Change to the Roche Enlarged Corporate Executive Committee

Rhea-AI Summary

Roche (OTCQX: RHHBY) announced Mark Dawson, M.D., Ph.D., will become Head of Roche Pharma Research and Early Development (pRED) and join the Enlarged Corporate Executive Committee, effective 1 May 2026.

Dawson joins from Peter MacCallum Cancer Centre, brings clinical and epigenetics expertise, multiple international honors, and academic appointments that position him to lead Roche pRED's next-generation therapy efforts.

Positive

• Mark Dawson appointed Head of pRED, effective 1 May 2026
• Joins Roche Enlarged Corporate Executive Committee as a member
• Extensive clinical-research background with major international awards

Negative

• None.

News Market Reaction – RHHBY

+2.72%

1 alert

+2.72% News Effect

On the day this news was published, RHHBY gained 2.72%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. Based in Basel, he will also become a member of the Enlarged Corporate Executive Committee.

Roche CEO Thomas Schinecker commented:

"Mark Dawson is a distinguished physician-scientist with a profound dedication to scientific excellence and patient care. His collaborative spirit and thoughtful leadership make him the ideal choice to lead pRED, and I am delighted to welcome him to our team."

Mark Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research. A leading expert in cancer biology, his work on chromatin regulation and epigenetics has been instrumental in defining the molecular mechanisms that drive cancer initiation and progression.

In addition to his clinical and research leadership, he holds a professorial appointment at the University of Melbourne and is an elected member of the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, and the European Molecular Biology Organisation (EMBO).

Mark earned his medical degree from the University of Melbourne in 1999, followed by specialist training in haematology and a Ph.D. from the University of Cambridge. His career is marked by prestigious international honors, including:

• The Prime Minister’s Prize for Science (Life Scientist of the Year, 2020)
• The Paul Marks Prize for Cancer Research
• The William Dameshek Prize (American Society of Hematology)
• Howard Hughes International Research Scholar

His extensive background as a clinician-researcher and his history of academic excellence position him to drive the next generation of innovative therapies at Roche pRED.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law. 

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 79 407 72 58	Nathalie Altermatt Phone: +41 79 771 05 25
Lorena Corfas Phone: +41 79 568 24 95	Simon Goldsborough Phone: +44 797 32 72 915
Karsten Kleine Phone: +41 79 461 86 83	Kirti Pandey Phone: +49 172 6367262
Yvette Petillon Phone: +41 79 961 92 50	Dr Rebekka Schnell Phone: +41 79 205 27 03

Attachment

• Media Release Changes to Enlarged CEC pRED English

FAQ

Who is Mark Dawson and what role will he take at Roche (RHHBY)?

Mark Dawson will become Head of Roche pRED, effective 1 May 2026. According to the company, he joins from Peter MacCallum Cancer Centre and brings clinical, research, and leadership experience in cancer biology and epigenetics.

When does Mark Dawson officially join Roche's Enlarged Corporate Executive Committee (RHHBY)?

Mark Dawson's appointment is effective 1 May 2026. According to the company, he will be based in Basel and simultaneously join the Enlarged Corporate Executive Committee on that date.

What scientific expertise does Mark Dawson bring to Roche pRED (RHHBY)?

Dawson is a leading expert in cancer biology, chromatin regulation and epigenetics. According to the company, his work has defined molecular mechanisms driving cancer initiation and progression.

What are Mark Dawson's notable honors and academic appointments mentioned by Roche (RHHBY)?

Dawson holds a professorial appointment and is an elected member of major academies with awards like the Prime Minister’s Prize for Science. According to the company, he also received international research prizes and society awards.

How might Mark Dawson's appointment affect Roche's early development pipeline (RHHBY)?

The appointment could strengthen leadership of early development and translational science. According to the company, Dawson's clinician-researcher background positions him to drive next-generation therapy efforts at pRED.